Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin’s lymphoma: Comparison of ILROG IS-RT and the GHSG IF-RT;Atemanhaltetechnik in tiefer Inspiration bei konventioneller APPA oder intensitätsmodulierter Radiotherapie beim Hodgkin-Lymphom: Vergleich zwischen der „IF-RT“ der ILROG und der „IS-RT“ der GHSG

Strahlentherapie und Onkologie

Volumn 191, Issue 9, 2015, Pages 717-725

  Kriz, Jan ^a   Spickermann, Max ^a   Lehrich, Philipp ^a   Schmidberger, Heinz ^b   Reinartz, Gabriele ^a   Eich, Hans ^a   Haverkamp, Uwe ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Complications; Hodgkin disease; Neoplasms, second primary; Organs at risk; Survival

Indexed keywords

ADULT; AGED; ANTERIOR POSTERIOR POSTERIOR ANTERIOR RADIOTHERAPY; ARTICLE; BREAST; BREATH HOLDING; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPARATIVE STUDY; ESOPHAGUS; FEMALE; HEART; HODGKIN DISEASE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; MIDDLE AGED; ORGANS AT RISK; RADIATION DOSE REDUCTION; SPINAL CORD; YOUNG ADULT; ADOLESCENT; COMPUTER ASSISTED RADIOTHERAPY; PROCEDURES; RADIATION DOSE; RADIATION PROTECTION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGED; FEMALE; HODGKIN DISEASE; HUMANS; MIDDLE AGED; RADIATION DOSAGE; RADIATION PROTECTION; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84940452200     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-015-0839-x     Document Type: Article

References (31)

1. Adams MJ, Lipsitz SR, Colan SD et al (2004) Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy. J Clin Oncol 22:3139–3148
2. Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, Ten Haken RK, Yorke ED (2010) Quantitative Analyses of Normal Tissue Effects in the Clinic. Int J Radiat Oncol Biol Phys 76:1–160
3. Burman C, Kutcher GJ, Emami B, Goitein M (1991) Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys 21:123–135
4. Chera BS, Rodriguez C, Morris CG et al (2009) Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin’s lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy. Int J Radiat Oncol Biol Phys 75:1173–1180
5. Darby SC, Cutter DJ, Boerma M et al (2010) Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys 76:656–665
6. De Sanctis V, Bolzan C, D’Arienzo M, Bracci S, Fanelli A, Cox MC et al (2012) Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: is it better than three dimensional conformal radiotherapy? Radiat Oncol 7:129-717X-7-129
7. Eich HT, Muller RP, Engenhart-Cabillic R et al (2008) Involved-node radiotherapy in early-stage Hodgkin’s lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol 184:406–410
8. Eich HT, Diehl V, Gorgen H, Pabst T, Markova J, Debus J et al (2010) Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28:4199–4206
9. Eich HT, Kriz J, Schmidberger H et al (2013) The German evidence-based guidelines for Hodgkin’s lymphoma. Aspects for radiation oncologists. Strahlenther Onkol 189:445–447
10. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE et al (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109–122
11. Engert A, Schiller P, Josting A et al (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21:3601–3608
12. Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P et al (2010) Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 363:640–652
13. Fiandra C, Filippi AR, Catuzzo P et al (2012) Different IMRT solutions vs. 3D-Conformal Radiotherapy in early stage Hodgkin’s lymphoma: dosimetric comparison and clinical considerations. Radiat Oncol 7:186
14. Gagliardi G, Constine LS, Moiseenko V et al (2010) Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 76:77–85
15. Girinsky T, Pichenot C, Beaudre A, Ghalibafian M, Lefkopoulos D (2006) Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin’s disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys 64:218–226
16. Girinsky T, van der Maazen R, Specht L et al (2006) Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 79:270–277
17. Goodman KA, Toner S, Hunt M et al (2005) Intensity-modulated radiotherapy for lymphoma involving the mediastinum. Int J Radiat Oncol Biol Phys 62:198–206
18. Haverkamp U, Norkus D, Kriz J et al (2014) Optimization by visualization of indices. Strahlenther Onkol 190:1053–1059
19. ICRU Report No. (2010) 83 International Commission on Radiation Units and Measurements—Prescribing, Recording, and Reporting Intensity–Modulated Photon-Beam Therapy. ICRU 83
20. Koeck J, Abo-Madyan Y, Eich HT et al (2012) Clinical relevance of different dose calculation strategies for mediastinal IMRT in Hodgkin’s disease. Strahlenther Onkol 188:653–659
21. Koeck J, Abo-Madyan Y, Lohr F et al (2012) Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy. Int J Radiat Oncol Biol Phys 83:268–276
22. Lohr F, Georg D, Cozzi L et al (2014) Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma: when should they be considered and which questions remain open? Strahlenther Onkol 190:864–866, 868–871
23. Lu NN, Li YX, Wu RY et al (2012) Dosimetric and clinical outcomes of involved-field intensity-modulated radiotherapy after chemotherapy for early-stage Hodgkin’s lymphoma with mediastinal involvement. Int J Radiat Oncol Biol Phys 84:210–216
24. Milano MT, Constine LS, Okunieff P (2007) Normal tissue tolerance dose metrics for radiation therapy of major organs. Semin Radiat Oncol 17:131–140
25. Ng AK, Kenney LB, Gilbert ES, Travis LB (2010) Secondary malignancies across the age spectrum. Semin Radiat Oncol 20:67–78
26. Nieder C, Schill S, Kneschaurek P, Molls M (2007) Comparison of three different mediastinal radiotherapy techniques in female patients: Impact on heart sparing and dose to the breasts. Radiother Oncol 82:301–307
27. Nilsson G, Holmberg L, Garmo H et al (2012) Distribution of coronary artery stenosis after radiation for breast cancer. J Clin Oncol 30:380–386
28. Paumier A, Ghalibafian M, Gilmore J et al (2012) Dosimetric benefit of intensity modulated radiotherapy combined with deep-inspiration breath-hold technique in patients with mediastinal Hodgkin’s Lymphoma. Int J Radiat Oncol Biol Phys 82:1522–1527
29. Specht L, Yahalom J, Illidge T et al (2014) Modern radiotherapy for Hodgkin lymphoma—field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 89:854–862
30. Weber DC, Peguret N, Dipasquale G et al (2009) Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supradiaphragmatic Hodgkin lymphoma: a comparative planning study. Int J Radiat Oncol Biol Phys 75:1578–1586
31. Wu VWC, Kwong DLW, Sham JST (2004) Target dose conformity in 3-dimensional conformal radiotherapy and intensity modulated radiotherapy. Radiother Oncol 71:201–206